Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease
about
Homodimerization Controls the Fibroblast Growth Factor 9 Subfamily's Receptor Binding and Heparan Sulfate-Dependent Diffusion in the Extracellular MatrixStem cells in human neurodegenerative disorders--time for clinical translation?Wnt5a cooperates with canonical Wnts to generate midbrain dopaminergic neurons in vivo and in stem cellsGermline competency of parthenogenetic embryonic stem cells from immature oocytes of adult mouse ovary.Cell-based therapies for Parkinson's disease: past, present, and futureConverted neural cells: induced to a cure?Selection Based on FOXA2 Expression Is Not Sufficient to Enrich for Dopamine Neurons From Human Pluripotent Stem CellsDifferentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian ratsFast and efficient neural conversion of human hematopoietic cellsParkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Downregulation of H19 improves the differentiation potential of mouse parthenogenetic embryonic stem cells.Development of histocompatible primate-induced pluripotent stem cells for neural transplantationWnt and extraocular muscle sparing in amyotrophic lateral sclerosisThe promise and perils of stem cell therapeutics.Treating non-motor symptoms of Parkinson's disease with transplantation of stem cellsCurrent protocols in the generation of pluripotent stem cells: theoretical, methodological and clinical considerations.Induced pluripotent stem cells in regenerative medicine: an argument for continued research on human embryonic stem cells.A dual-hit animal model for age-related parkinsonism.Stem cell-derived dopamine neurons for brain repair in Parkinson's disease.Strategies for the development of cell lines for ex vivo gene therapy in the central nervous system.Stem cell-based therapies in Parkinson's disease: future hope or current treatment option?Cell therapeutics in Parkinson's disease.Guiding differentiation of stem cells in vivo by tetracycline-controlled expression of key transcription factors.Cellular programming and reprogramming: sculpting cell fate for the production of dopamine neurons for cell therapy.Cell therapy for Parkinson's disease: what next?Adult subventricular zone neural stem cells as a potential source of dopaminergic replacement neuronsAdult human neural stem cell therapeutics: Current developmental status and prospectThe role of nonhuman primate models in the development of cell-based therapies for Parkinson's disease.Regeneration of dopaminergic neurons after 6-hydroxydopamine-induced lesion in planarian brain.Roles of FGF20 in dopaminergic neurons and Parkinson's disease.Stem cells as in vitro model of Parkinson's disease.Cell transplantation and gene therapy in Parkinson's disease.Derivation of high-purity definitive endoderm from human parthenogenetic stem cells using an in vitro analog of the primitive streak.RGD-peptide modified alginate by a chemoenzymatic strategy for tissue engineering applications.
P2860
Q27646372-6CD3AB8F-2B21-4BCE-B39E-2B99697251E6Q27687068-8E5FFAE0-E482-46E7-B15F-DC105920B89CQ28587554-5F8BE677-12C8-4774-914F-017D18F33C34Q30498336-39637E6D-0185-41E1-89E5-CD9BA6DDE4F6Q33818127-5E35E8F0-4A48-4256-BFE6-4CADF38C5B5EQ33924616-2E9487B1-3E38-4A67-B432-6330D2C4BC83Q34109406-736CD98E-7FF8-4B38-BC22-FFCB95C55B24Q34115609-D0934D81-09F4-4960-B526-232DF15713A0Q34684538-C75DCE1E-3DBE-4BDE-A587-FB04460CC07AQ35614156-2FE41636-E667-4DA9-9D79-3E5D427C3311Q35895288-039156E6-C1E9-457C-A88C-E9B0963BB520Q35924439-72656229-8442-41B0-96EC-B8D156022ACDQ36086193-F275D6A4-DB8D-4A45-9A61-16824578907AQ36776231-463A7587-9137-47F2-8B4E-A45EA01EB182Q36790753-FE61B933-26DC-4BD7-BDD8-23713D51934DQ37194068-6F8D0928-A27E-4ADA-9EC5-E388FEDEDA24Q37598915-DC140D9F-7A7D-4587-BEBC-A35C50911358Q37620482-CCD9C413-E61C-495B-BB11-9BD8DE69113EQ37704372-356DB058-6212-4BDA-B195-983EC91A3FE0Q37822930-0FBFFFA7-476E-46AA-ACF7-56139A567049Q37857754-453A7544-233B-466C-8311-9A6A0F979399Q37929026-74692387-A584-4448-8C5F-1FF1229BC36BQ37999164-36C877CB-1C15-4DA0-AF6D-014CD7E42C80Q38044388-BA63C571-AB8E-415C-8F92-BDC8586C903CQ38079793-ADF82852-8FE6-49D4-975E-527A71176D40Q38191589-19A211E0-8255-4168-B09B-983A6FA94F98Q38332493-9AAF3FF7-4D93-4EA4-899B-899937F05FCCQ39192172-91D1914A-0F3A-4736-B955-96FD0A0F45FEQ39699314-CD95D1C4-5224-4CDB-B7E0-D79FC99CBFACQ41237490-86D3333E-1F2E-4FE8-BE01-FEB6B813EADFQ42159528-65DEAAFC-A8DC-4002-BE46-4575C0C19025Q44297524-014F1CF3-708F-4573-8893-E9A4CAC955D6Q50518742-DB84FF05-72EB-4A4C-BDED-1465FCB56654Q51735435-372F4ACC-BBD4-460E-91FB-5F706B10E5C9
P2860
Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Parthenogenetic dopamine neuro ...... perimental Parkinson's disease
@en
Parthenogenetic dopamine neuro ...... erimental Parkinson's disease.
@nl
type
label
Parthenogenetic dopamine neuro ...... perimental Parkinson's disease
@en
Parthenogenetic dopamine neuro ...... erimental Parkinson's disease.
@nl
prefLabel
Parthenogenetic dopamine neuro ...... perimental Parkinson's disease
@en
Parthenogenetic dopamine neuro ...... erimental Parkinson's disease.
@nl
P2093
P2860
P50
P356
P1433
P1476
Parthenogenetic dopamine neuro ...... perimental Parkinson's disease
@en
P2093
Casper Reske-Nielsen
Hyojin Lee
Kai C Sonntag
Michaela Patterson
Takahito Yoshizaki
P2860
P304
P356
10.1093/BRAIN/AWN144
P407
P577
2008-07-22T00:00:00Z